Breaking the backbone of triple-negative breast cancers

Putting the brakes on an abundant growth-promoting protein causes breast tumors to regress, according to a study published on March 19th in the Journal of Experimental Medicine.

Triple-negative lack all of the known growth receptors that serve as treatment targets in other types of breast cancer, making this the most clinically challenging subtype of the disease. Patients with these tumors tend to relapse earlier and have shorter disease-free survival.

Andrei Goga and colleagues now show that triple-negative breast tumors express elevated levels of the growth-driving protein called MYC. MYC activity was required for the growth of these , and blocking a MYC-cooperating protein, CDK, caused triple-negative tumors to shrink in mice.

Together, these results identify a potential new target for triple-negative tumor treatment.


Explore further

Five-year U.K. breast cancer trial starts

More information: Horiuchi, D., et al. 2012. J. Exp. Med. doi:10.1084/jem.20111512
Journal information: Journal of Experimental Medicine

Citation: Breaking the backbone of triple-negative breast cancers (2012, March 19) retrieved 15 December 2019 from https://medicalxpress.com/news/2012-03-backbone-triple-negative-breast-cancers.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments